Slide 1: OraSure 4Q21 Earnings
OraSure 4Q21 Earnings February 23, 2022 EXHIBIT 99.2
Slide 2: Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to products, product development activities, regulatory submissions and authorizations and other matters. Forward-looking statements are not guarantees of future performance or
Slide 3: 4Q21 and FY21 Financial Results
4Q21 and FY21 Financial Results FINANCIAL METRIC 4Q21/FY21 RESULTS 4Q20/FY20 RESULTS YEAR-OVER-YEAR GROWTH RATE Quarterly Revenue $63.6 million $62.9 million 1% Annual Revenue $233.7 million $171.7 million 36% Annual Revenue Diagnostics $90.0 million $65.2 million 38% Annual Revenue Molecular Soluti
Slide 4: 4Q21 and FY21 Diagnostic Business Unit Results
4Q21 and FY21 Diagnostic Business Unit Results Full Year 2021 % vs PY Q4 2021 % vs PY Total DX BU $90.0M +38% $32.7M +58% Core DX $67.3M +3.5%* $17.9M (13)% Core DX US $36.7M +13.3% $8.2M (2)% Core DX OUS $30.6M (6.2)%* $9.7M (20)% COVID-19 $22.7M NM $14.8M NM * Ex Gates Subsidy impact, Full Year 20
Slide 5: New Government Programs Expand U.S. COVID-19 Point-of-Care Testing Market
New Government Programs Expand U.S. COVID-19 Point-of-Care Testing Market *Source: Epidemiology data, OSUR estimates Biden administration announces purchase of an additional 1 billion free rapid antigen tests Commercial and Medicare/Medicaid reimbursement for up to 8 tests per month per person with
Slide 6: InteliSwab Expansions
InteliSwab® Expansions InteliSwab® detects Omicron with same limit of detection as other variants of concern and original Wuhan strain Pediatric indication for use in children ages 2-14 when performed by an adult Launching the new reporting app, InteliSwab ® Connect
Slide 7: InteliSwab Operations Restructured
InteliSwab® Operations Restructured – New Operations Leadership & Outside Expertise Mapped Processes & Identified Bottlenecks Implement Solutions Impact Faster to Execute
Slide 8: 4Q21 and FY21 Molecular Solutions Business Unit Results
4Q21 and FY21 Molecular Solutions Business Unit Results FINANCIAL METRIC 4Q21/FY21 RESULTS 4Q20/FY20 RESULTS YEAR-OVER-YEAR GROWTH RATE Quarterly Core Molecular Solutions $22.9 million $19.3 million 19% Quarterly COVID-19 Kits $8.0 million $22.9 million (65%) Annual Core Molecular Solutions $89.5 mi
Slide 9: Enabling Multi-Omic Discovery and Diagnostics Through Innovation
Enabling Multi-Omic Discovery and Diagnostics Through Innovation Collection and stabilization Sample preparation and extraction Sample prep and data generation Data integration Insights and visualization Genomics Transcriptomics Epigenomics Proteomics Metabolomics Microbiome Transcriptomics Current
Slide 10: Enabling Multi-Omic Discovery and Diagnostics Through Innovation
Meta-transcriptome Launch FDA Clearance for Gut Kit New Cancer Chemistry Enabling Multi-Omic Discovery and Diagnostics Through Innovation
Slide 11: Molecular Solutions COVID-19 Kit Revenue
Molecular Solutions COVID-19 Kit Revenue Increasing transition from central lab testing to POC testing options GOING FORWARD: International expansion Broader launch in viral surveillance
Slide 12: Consolidated Revenue by Quarter
Consolidated Revenue by Quarter Revenue (in mil.) Record Diagnostic and Molecular Solutions Revenue in FY21 Record revenue in 4Q21
Slide 13: Financial Results
Financial Results ‘Dee Mands ded Decenber 31 7a 70 asus f Opertions Nereaus 5 as ass Cast of products md anv ol 3685 24671 Gros prot —a sr opmengepaes —— Reeudundderelpmat 00 oss Sibs mimelating sosis 910 Gaurd adaiasree lasts man hg fer vl of ecqurtemaehted entngse coe, m2 aa Taslqpentngepases arr
Slide 14: Summary
Summary Commercially tied to high growth areas of healthcare such as consumer/clinical genomics and shift to direct-to-patient/near patient testing Increased investment in internal R&D pipeline and reinvigorating innovation Significant opportunity with InteliSwab™ to drive growth and fund additional
Slide 15: Q&A
Q&A OraSure Technologies oNAgenoTeK” Diversigen’ Wnovosanis